a:head

a:head bio AG is an Austrian biotech company using human brain organoids to develop novel therapeutics for the treatment of various neurological disorders.

a:head’s main focus is on epilepsy with Dravet syndrome, a rare but severe genetic epileptic encephalopathy, being the initial disease target.